

1 **Gene-Specific Common Deletion Regions and Detection of Gene Copy Number**

2 **Deletion**

3 **Running title:** Gene-specific common deletion regions

4 Yuan Tian, Ph.D. ^{1#}, Rui Xing, Ph.D. ^{2#}, Jing Zhou^{1#}, Juanli Qiao, Ph.D. ¹, Zhaojun Liu, Ph.D. ¹, Liankun Gu¹,
5 Baozhen Zhang, Ph.D. ¹, Youyong Lu, M.D. ², Dajun Deng, M.D. ^{1*}

6 ¹ Key Laboratory of Carcinogenesis and Translational Research (MOE/Beijing), Division of Etiology, Peking
7 University Cancer Hospital and Institute, Beijing, 100142, China;

8 ² Key Laboratory of Carcinogenesis and Translational Research (MOE/Beijing), Division of Tumor Biology,
9 Peking University Cancer Hospital and Institute, Beijing, 100142, China

10 # Equal first authors

11 ***Corresponding author:** Dajun Deng, Key Laboratory of Carcinogenesis and Translational Research
12 (MOE/Beijing), Division of Etiology, Peking University Cancer Hospital and Institute, Fu-Cheng-Lu #52,
13 Haidian District, Beijing, 100142, China, Phone:+8610-88196752 (E-mail: dengdajun@bjmu.edu.cn)

14 **Word count:** 3945

15

1 **Abstract**

2 A feasible method to detect somatic copy number deletion (SCND) of tumor suppressor genes is still absent
3 up to date. To overcome the obstacle of SCND detection, we analyzed genomic coordinates of gene deletion
4 fragments using the Catalogue Of Somatic Mutation In Cancer (COSMIC) datasets. Interstitial
5 base-resolution deletion/fusion coordinates for *CDKN2A* were extracted from published articles and our
6 whole genome sequencing (WGS) datasets. The results showed that estimated common deletion regions
7 (CDRs) were observed in many tumor suppressor genes, such as *ATM*, *CDKN2A*, *FAT1*, *miR31HG*, *PTEN*, and
8 *RB1* in the SNP array-based COSMIC datasets. A 5.1-kb base-resolution CDR could be identified in >90%
9 cancer samples by sequencing. Using the true *CDKN2A* CDR as a PCR target, a multiplex quantitative PCR
10 assay P16-Light was programmed to detect *CDKN2A* gene copy number with a lower detection limit of 20%.
11 P16-Light was further confirmed with WGS as the gold standard among cancer tissue samples from 139
12 patients. In conclusion, CDRs are common in many tumor suppressor genes. The 5.1-kb *CDKN2A* CDR was
13 found in >90% cancers containing *CDKN2A* deletion. The *CDKN2A* CDR was used a potential target for
14 developing the P16-Light assay to detect *CDKN2A* SCND and amplification for routine clinical practices.

15 **Key words:** somatic copy number variation (SCNV); common deleted region (CDR); tumor suppressor gene;
16 *CDKN2A*; whole genome sequencing (WGS)

17

1 Introduction

2 Somatic copy number variations (SCNVs) of tumor related genes are landmarks of human cancers (1,2).
3 Somatic copy number deletion (SCND) and amplification are two kinds of well-known SCNVs. However,
4 current gene copy number detection methods, including microsatellite instability (MSI), loss/gain of
5 heterozygosity (LOH/GOH), fluorescence-in-situ hybridization (FISH), whole genome sequencing (WGS) or
6 whole exome sequencing (WES), are not sensitive enough or too costly for routine clinical use. While the
7 amplification of oncogenes (such as *EGFR*, *c-ERBB2*, *c-MYC*, and *c-MET*) are increasingly driving
8 decision-making for precise cancer treatments, clinical applications of SCND of tumor suppressor genes,
9 including *CDKN2A*, are still rare owing to the lack of a feasible detection assay.

10 The frequency of *CDKN2A* SCND detected by single nucleotide polymorphism (SNP) microarray, WGS or
11 WES was found to range from 30% to 60% in bladder cancer, melanoma, head and neck cancer, pleural
12 mesothelioma, glioblastoma, and esophageal squamous cell cancer (ESCC) with an average frequency of
13 13% in pan-cancer datasets in The Cancer Genome Atlas (TCGA) (Figure S1A) (2-6). *CDKN2A* deep-deletion is
14 associated with downregulation of the *CDKN2A* gene expression, while *CDKN2A* amplification is associated
15 with upregulation of the *CDKN2A* gene expression in Pan-TCGA cancers (Figure S1B). It is well known that
16 genetic *CDKN2A* inactivation contributes to malignant transformation, cancer metastasis, and therapy
17 sensitivity of cancers to drugs, including CDK4/6 inhibitors and their combination with PD-1 blockades (7-11).
18 Therefore, a convenient and sensitive assay to detect *CDKN2A* SCND is eagerly awaited.

19 In the present study, we characterized patterns of estimated genomic coordinates for SCNDs in a set of
20 tumor suppressor genes using public Catalogue Of Somatic Mutations In Cancer (COSMIC) SCNV datasets
21 and found common deletion regions (CDRs) in many frequently deleted genes. Then, we further defined a
22 5.1-kb base-resolution CDR within the *CDKN2A* gene using sequencing data for the first time. A sensitive
23 P16-Light assay targeted to the *CDKN2A* CDR was established for clinical practices.

24 Methods & Material

25 COSMIC and TCGA SCNV datasets

26 SNP6 array-based Estimated genomic coordinates of interstitial copy number deletion/fusion of the *CDKN2A*
27 gene in cancer cell lines (n=273) with homozygous *CDKN2A* deletion and estimated genomic coordinates of
28 deep-deleted fragments of *CDKN2A*, *PTEN*, *RB1*, and other frequently deleted genes in cancer tissues were
29 downloaded from were downloaded from the Copy Number Analysis (CONA) datasets in the COSMIC
30 project (Data file 1-11) (12).

1 **Patients, tissues, and DNA preparation**

2 Frozen fresh GC and paired surgical margin (SM) tissue samples were collected from 156 patients in the
3 WGS study (13). These samples were frozen in liquid nitrogen about 30 min after surgical dissection and
4 then stored in a -80° C freezer for 2-5 yrs. Clinicopathologic information were also obtained. The 2010
5 UICC tumor-node-metastasis (TNM) system was used to classify these GCs (14). Genomic DNA was extracted
6 from these samples with a phenol/chloroform method coupled with RNase treatment. Concentrations of
7 these DNA samples were determined with NanoVue Plus (Biochrom LTD, Cambridge, UK). DNA samples with
8 OD_{260nm}/OD_{280nm} ratios ranging from 1.7 to 1.9 were used for detection of gene copy number as described
9 below.

10 **Optimized quantitative multiplex PCR assay (P16-Light) to detect *CDKN2A* copy number**

11 A number of multiplex primer and probe combinations were designed based on the best multiplex primer
12 probe scores for conservative sequences within the CDR in the *CDKN2A* (HGNC: 1787) and *GAPDH* (HGNC:
13 4141) gene sequences by Bacon Designer 8 software. Multiplex PCR assays were established according to
14 the Applied Biosystems (ABI) TaqMan universal PCR master mix manual. The performance of these assays
15 for the detection of *CDKN2A* copy numbers was compared with each other. Finally, a multiplex primer and
16 probe combination targeted to *CDKN2A* intron-2 was selected (Table 1) and their components'
17 concentrations were optimized. Each multiplex PCR assay was carried out in a total volume 20 μ L that
18 included 5-10 ng of input DNA, 10 μ M of forward and reverse primers and probe for *CDKN2A* intron-2, 10
19 μ M forward and reverse primers and probe for *GAPDH*, and 10 μ L of 2 x TaqMan Universal Master Mix II
20 with uracil-N-glycosylase (Kit-4440038, ABI, Lithuania). The PCRs were performed in triplicate in a
21 MicroAmp Fast Optical 96-Well Reaction Plate with a barcode (0.1 mL; ABI, China) with an ABI 7500 Fast
22 Real-Time PCR System. The specific conditions of the PCR were as follows: initial incubation for 10 min at
23 95°C, followed by 40 cycles of 95°C for 20 sec and 58°C for 60 sec. When Ct value for *GAPDH* input for a
24 sample was 34 or fewer cycles, this sample was considered as *CDKN2A* SCNV informative. The specificity of
25 PCR reaction was monitored through running gel. Distilled water was used as no template control for each
26 experiment.

27 **Definitions of *CDKN2A* CDR deletion-positive and amplification-positive**

28 We used the genomic DNA from A549 cells containing no *CDKN2A* allele to dilute genomic DNA from RKO
29 cells containing 2 wild-type *CDKN2A* alleles, and then we set the standard curve according to the relative
30 copy number of the *CDKN2A* gene at different dilution concentrations. The Δ Ct value and relative copy

1 number for the *CDKN2A* gene were calculated using the *GAPDH* gene as the internal reference. When the
2 *CDKN2A* copy number in the A549-diluted template was consistently lower than that in the RKO control
3 template, and the difference was statistically significant (t-test, $p < 0.05$), it was judged that the lowest
4 dilution concentration was the detection limit of *CDKN2A* deletion (the difference in *CDKN2A* copy number
5 between the 100% RKO template and 80% RKO template spiked with 20% A549 DNA). When the *CDKN2A*
6 relative copy number in a tissue sample was significantly lower or higher than that of the paired SM sample,
7 the sample was defined as somatic *CDKN2A* CDR deletion-positive or amplification-positive, respectively.
8 For each experiment, the 100% A549, 100% RKO, and 20% A549 + 80% RKO DNA mix controls were
9 analyzed.

10 **Quantitative detection of *CDKN2A/P14^{ARF}* exon-1 β copy number by PCR assay (P14-qPCR)**

11 The copy number of *CDKN2A* exon-1 β was detected using the primer and probe set (Table 1) as previously
12 reported (15). When the relative copy number of *CDKN2A* exon-1 β in a tissue sample was significantly lower
13 or higher than that of the paired SM sample, the sample was defined as somatic *CDKN2A/P14^{ARF}*
14 deletion-positive or amplification-positive, respectively.

15 **Call for *CDKN2A* interstitial deletion/fusion and calculate purity of cancer cells in the GC WGS datasets**

16 We used Meerkat 23 to predict somatic SVs and their breakpoints in WGS datasets (accession numbers,
17 EGAD00001004811 with 36 \times of sequencing depth) for gastric adenocarcinoma samples from 168 patients
18 using the suggested parameters (13). This method used soft-clipped and split reads to identify candidate
19 breakpoints, and precise breakpoints were refined by local alignments. *CDKN2A* deletion information of 157
20 GC samples was obtained from WGS datasets. We also estimated copy number profiling over 10-kb
21 windows with Patchwork 28 and calculated the ratio of standardized average depth between normal tissue
22 and tumor tissue (log₂R ratio). The purity and ploidy of each tumor were calculated using ABSOLUTE
23 software (16).

24 **Cell lines and cultures**

25 The *CDKN2A* allele homozygously deleted cell line A549 (kindly provided by Dr. Zhiqian Zhang of Peking
26 University Cancer Hospital and Institute) were grown in RPMI-1640 medium, and the RKO cell line
27 containing two wild type *CDKN2A* alleles was purchased from American Type Culture Collection and grown
28 in DMEM media. The medium was supplemented with 10% (v/v) fetal bovine serum (FBS). These cell lines
29 were tested and authenticated by Beijing JianLian Genes Technology Co., Ltd. before they were used in this
30 study. A Goldeneye™ 20A STR Identifier PCR Amplification kit was used to analyze the STR patterns.

1 **Statistical analysis**

2 Chi-square or Fisher's exact tests were used to compare the proportion of *CDKN2A* SCND or amplification
3 between different groups of tissue samples. Student t-test was used to compare the proportion of the
4 *CDKN2A* gene copy number between genomic DNA samples. All statistical tests were two-sided, and *p* value
5 less than 0.05 was considered to be statistically significant.

6 **Results**

7 **Prevalence of estimated CDRs within various tumor suppressor genes**

8 It has been previously reported that homozygous deletion of approximately 170 kilobase pairs (kb),
9 including the *CDKN2A* locus, can be detected in human cancers by MSI analyses (17). SCND inactivates the
10 *CDKN2A* gene in 273 human cancer cell lines according to the COSMIC dataset (Data file 1). We found that
11 an 8-kb estimated *CDKN2A* CDR could be detected among these cell lines through ording "start" coordinates
12 of these breaking points (Figure S1). To investigate the prevalence of CDRs within tumor suppressor genes in
13 human cancer tissues with a high deletion frequency (1,2), we further downloaded the estimated genomic
14 coordinates for deletion fragments that overlap with these genes, respectively. We found that CDRs could
15 be detected not only within the *CDKN2A* gene (Figure 1A; about 17-kb), but also within *ATM* (middle to
16 downstream), *FAT1* (promoter to middle), *mir31HG* (promoter to exon-1), *PTEN* (promoter to exon-1), and
17 *RB1* genes (promoter to intron-2) (Figure 2; about 158-kb, 23-kb, 33-kb, 5-kb, and 2442-kb, respectively)
18 (Data file 2-7). No CDR could be observed within *CCSER1*, *FHIT*, *LRP1B*, and *WWOX* genes according to the
19 SNP-array data (Data file 8-11).

20 **Characterization of a true *CDKN2A* CDR at the base-resolution in human cancers**

21 It was reported that the error in *CDKN2A* breakpoint estimation based on SNP-array data is roughly 10-kb
22 (18). To characterize true genomic coordinates of *CDKN2A* deletion fragments in cancers, we extracted
23 base-resolution sequence information of interstitial *CDKN2A* deletions from available published articles and
24 our sequencing data (Data file 12) (19-28). We found a 5.1-kb CDR (chr9: 21,970,277 - 21,975,386, hg19)
25 that spanned from the *P16^{INK4a}* promoter to intron-2 in 83 (90%) of 92 reported cancer cell lines or tissue
26 samples containing interstitial *CDKN2A* deletions (Figure 1B, blue lines). This CDR sequence is the same as
27 the *CDKN2A* deletion fragment in the HCC193 lung cancer cell line (25). The CDR coordinates were also
28 confirmed in our WGS datasets (average sequencing depth, 36×) of 18 (100%) of 18 GCs (13), in which
29 interstitial *CDKN2A* deletions/fusions were identified (Figure 1B, purple lines; Data file 12).

1 It is well known that germline *CDKN2A* inactivation can lead to a high predisposition for melanoma and
2 pancreatic cancer (29-31). Interestingly, we found that 14 (93.3%) of 15 *CDKN2A* allelic variants in the
3 Online Mendelian Inheritance in Man (OMIM) database are located within the CDR sequence, especially in
4 *CDKN2A* exon-2 (Figure S3) (32,33).

5 In addition, both *P16^{INK4a}* and *P14^{ARF}* mRNAs are transcribed from the human *CDKN2A* gene at
6 chromosome 9p21 but with different transcription start sites; they share the same exon-2 but have different
7 translation reading frames. Because the *CDKN2A* exon-2 located within the true CDR is the essential exon
8 for coding *P16^{INK4a}* and *P14^{ARF}* proteins, the above findings indicate that *P16^{INK4a}* and *P14^{ARF}* are
9 co-inactivated in 87% (96/110) of human cancer cell lines and tissues containing *CDKN2A* CDR deletion
10 (Figure 1B).

11 **Establishment of a convenient PCR assay (P16-Light) to detect somatic *CDKN2A* CDR deletion**

12 The current clinical method FISH for detecting SCND is composed of a set of biotin-labeled probes that
13 should cover at least 50-kb DNA sequence. Thus, FISH is not a suitable method for detecting the copy
14 number deletion of the 5.1-kb *CDKN2A* CDR. To provide a convenient way for routine clinical use, we
15 designed and experimentally evaluated a set of multiplex quantitative PCR assays and finally optimized the
16 *CDKN2A* CDR-specific quantitative multiplex PCR assay called P16-Light for detecting the copy number of a
17 129-bp amplicon within the *CDKN2A* intron-2 (Figure 3A), which covers 86% (94/110) of known *CDKN2A*
18 deletion fragments (Figure 1B, violet line).

19 The copy number of the *GAPDH* gene was used as the internal reference. Genomic DNA from human
20 A549 cells (with homozygous deletion of *CDKN2A* alleles) and RKO cells (with 2 wild-type *CDKN2A* alleles)
21 were used as *CDKN2A* CDR deletion-positive and deletion-negative controls, respectively. The amplification
22 efficiency of two amplicons in *GAPDH* and *CDKN2A* were very similar (Figure 3B). No template inhibition
23 was observed when the amount of template DNA ranged from 10 to 0.63 ng (Figure 3C). The proportions of
24 *CDKN2A* CDR copy number were linearly correlated with the ratios (0 - 100%) of RKO cell DNA and A549 cell
25 DNA in the input mixtures (10 ng/reaction) when the A549 DNA was spiked in at different proportions for
26 the P16-Light analyses (Figure 3D). Furthermore, there was a high reproducibility when DNA with
27 homozygous deletion of *CDKN2A* was present in $\geq 20\%$ of the cells verified in ten experimental repeats
28 performed on different days (Figure 3E). Thus, when the proportion of *CDKN2A* copy number was
29 significantly decreased (or increased) in a sample relative to the paired normal control (t-test, $p < 0.05$) in the
30 P16-Light analyses, the sample would be defined as *CDKN2A* SCND-positive (or amplification-positive).

1 **Comparison of P16-Light with WGS datasets**

2 As we described above, information on interstitial copy number deletion/fusion of the *CDKN2A* gene was
3 extracted from WGS datasets for 156 of 168 GC patients enrolled in a GC genome study (13) and a total of
4 18 *CDKN2A* deletion/fusion coordinates at the base-resolution were detected in 17 (10.8%) GCs (Data file 12
5 and 13). To compare the performance of P16-Light with WGS, we analyzed the status of SCNVs, including
6 SCND and amplification, of the *CDKN2A* gene in 156 of these GCs with enough amounts of genomic DNA
7 samples with P16-Light using the paired surgical margin tissue (SM) as the diploid reference (Data file 13).
8 *CDKN2A* SCND and amplification were detected in 40 (25.6%) and 34 (21.8%) of these GCs, respectively. The
9 P16-Light analysis was confirmed by the WGS results: the frequency of *CDKN2A* SCND (or amplification) by
10 P16-Light was significantly higher (or lower) in 17 GCs containing interstitial *CDKN2A* deletion/fusion than
11 those 139 GCs without (chi-square test, $p < 0.028$; Figure 4A). These results also indicate that there is a
12 significantly higher sensitivity for detecting *CDKN2A* SCND by the quantitative P16-Light assay than the
13 hemi-quantitative WGS.

14 Moreover, it is well known that the proportion of cancer cells in tissue samples (ie. sample purity) may
15 affect the detection values of various genome data. To study whether cancer cell proportion disturbs
16 detection of *CDKN2A* SCNVs, we calculated cancer cell proportion in above GC samples using WGS data
17 (Data file 13). We found that the difference in sample purity between GC subgroups with the different
18 status of *CDKN2A* SCNVs was not statistically significant (t-test, $p = 0.075$; Figure 4B), although the proportion
19 was slightly higher in the GCs with *CDKN2A* SCND than those without. No correlation was observed
20 between the proportion of cancer cells and relative copy number of the *CDKN2A* gene among these GCs
21 (Figure 4C).

22 **Comparison of P16-Light with P14-qPCR assay**

23 The P14-qPCR assay was previously established for detecting the copy number of *CDKN2A/P14^{ARF}*
24 exon-1 β (15). Two amplicons in the P16-Light and P14-qPCR assays cover 98% (108/110) of known *CDKN2A*
25 deletion fragments (Figure 1B, violet and green lines). Therefore, we further compared the performance of
26 P16-Light, P14-qPCR, and their combination using GCs and paired SM samples from patients who were
27 recently included in the cross-sectional cohort in our association study (34). GC samples ($n = 139$) with
28 enough amount of genomic DNA were used in P14-qPCR analysis (Data file 14). The SCND-positive rate for
29 *P14^{ARF}* was similar to that for the *CDKN2A* CDR (31.7% vs 36.7%) (Table 2). *CDKN2A* SCND was found only in
30 19 GCs by both assays. While *CDKN2A* CDR SCND was significantly associated with distant metastasis of GC

1 (odd ratio=4.09, $p<0.001$), no association was observed between $P14^{ARF}$ SCND and GC metastasis. Using
2 merged *CDKN2A* SCND data (*CDKN2A* CDR SCND-positive and/or $P14^{ARF}$ SCND-positive), only a weaker
3 association was observed. These results suggest that individual P16-Light alone may be good enough for
4 detecting *CDKN2A* SCND in tissue samples.

5 Discussion

6 Somatic copy number deletion and amplification are two main kinds of SCNVs. The detection of copy number
7 amplification of oncogenes is routinely used for precise cancer treatments. However, the detection of SCND
8 of tumor suppressor genes is absent and its significance in clinical practices is not well studied. The reason
9 should be the lack of feasible detection approaches. Here, we report that there are CDRs in many tumor
10 suppressor genes, such as *CDKN2A*, *miR31HG*, *PTEN*, and *RB1*, which are commonly inactivated by SCND in
11 various human cancers (1,2). Notably, we characterized, for the first time, the 5.1-kb true CDR from the
12 *CDKN2A/P16^{INK4A}* promoter to intron-2 in >90% *CDKN2A*-deleted cancers. Using the *CDKN2A* CDR as a PCR
13 target, we further established the feasible P16-Light assay to detect *CDKN2A* SCND and amplification in
14 tissue samples. These findings indicate that CDRs are prevalent sequences in tumor suppressor genes, and
15 characterization of the base-resolution genomic coordinates of CDRs could enable us to setup convenient
16 methods for SCND detection of genes.

17 Interstitial deletion/fusion is the main type of *CDKN2A* SCND and the breaking/fusing coordinates for
18 *CDKN2A* SCNDs in cancer genomes are diverse, which blocks the establishment of a feasible detection assay
19 for *CDKN2A* SCND, although many efforts have been afforded (20). In the present study, we initially found
20 the 8~17-kd estimated *CDKN2A* CDR in both monoclonal cancer cell lines and cell-heterogenous cancer
21 tissues with *CDKN2A* copy number deletion according to the SNP-array datasets from COSMIC and TCGA
22 projects (1,12). Then, we further characterized the 5.1-kb true CDR at the base-resolution within the
23 *CDKN2A* gene in cancer genomes using DNA sequencing data (19-28), and confirmed the CDR using WGS
24 datasets in all 18 GCs containing *CDKN2A* SCND (13). Because the true *CDKN2A* CDR was observed in more
25 than 90% of *CDKN2A*-deleted cancer samples and the P16-Light assay is highly reproducible and convenient,
26 the quantitative P16-Light assay should be considered as a viable assay for detecting *CDKN2A* SCNVs in
27 clinical practices. This is supported by the result that *CDKN2A* SCND by P16-Light was significantly associated
28 with GC metastasis, and further supported by the results of our prospective study, in which *CDKN2A* SCND
29 was closely associated with hematogenous metastasis of GCs (34). In another long-term prospective study,
30 we also found that *CDKN2A* SCND and amplification by P16-Light were significantly associated with

1 malignant transformation and complete regression of mild or moderate esophageal squamous cell dysplasia,
2 respectively (Fan et al. submitted for publication). The results of these studies also suggest that the
3 sensitivity of 20% for the P16-Light assay may be good enough for routine clinical use.

4 WGS is generally used as a kind of gold standard to study structural alterations of genomic DNAs,
5 especially for interstitial gene copy deletion/fusions. However, WGS is a cost assay and its accuracy
6 depends on sequencing depth, WGS at sequencing depth 36× would be considered as the hemi-quantitative
7 assay. In our calling *CDKN2A* SCND coordinate processes, it was found that 18 *CDKN2A* SCND coordinates
8 were identified in 17 (10.8%) of 157 GCs, which was consistent with the frequency (11.4% =50/438) of
9 homozygous deletion of *CDKN2A* in GCs in WES or WGS sequencing datasets (Data file 14) (35). The positive
10 rate (25.6%) of *CDKN2A* SCND in 156 GCs with enough genomic DNA samples in the P16-Light analysis was
11 more than twice of WGS. And the results of P16-Light analyses were significantly correlated with those of
12 WGS. These phenomena suggest that P16-Light is a much more sensitive, convenient, and less expensive
13 assay than WGS.

14 P14-qPCR is a method used to detect the copy number of *CDKN2A/P14^{ARF}* exon-1 (15). Although the
15 combination of P16-Light with P14-qPCR may detect both SCNDs overlapped with the *CDKN2A* CDR and not
16 overlapped with the *CDKN2A* CDR, the results of our comparison analysis among 139 GC patients showed
17 that detecting *CDKN2A* SCND by individual P16-Light may be good enough for clinical practices because
18 combination with P14-qPCR could not improve the performance of P16-Light. However, for other genes
19 such as *RB1* and *PTEN*, whether a qPCR array needs to be employed for detecting their SCNVs should be
20 studied case by case.

21 Generally, IHC is a popular method used to detect expression changes of protein-coding genes. For
22 example, P16^{INK4A} overexpression in cervical mucosa samples is currently used for rapidly HPV infection
23 screening. We compared the status of P16^{INK4A} expression by IHC between GCs with *CDKN2A* SCND (n=4)
24 and without *CDKN2A* SCND (n=12) and did not find any difference in the P16^{INK4A} positive-staining rate
25 between these GCs (3/4 vs. 9/12). The expression level of *CDKN2A/P16^{INK4A}* is not only affected by SCNVs, but
26 also regulated by the methylation status of CpG island, histone modifications, and high-risk HPV infection
27 (36,37). These factors may partially account for the insistence between IHC and P16-Light.

28 The driver function of the *CDKN2A* gene in cancer development is enigmatic. *P16^{ink4a}* inactivation
29 contributes less than *P19^{arf}* (the murine counterpart of human *P14^{ARF}*) inactivation to cancer development in
30 mice, while *P16^{INK4a}* inactivation contributes more than *P14^{ARF}* inactivation to cancer development in

1 humans (38,39). The exact mechanisms leading to the difference among species is still unclear. Here, we
2 reported that approximately 87% of genetic $P16^{INK4a}$ inactivation by $CDKN2A$ SCND is accompanied by $P14^{ARF}$
3 inactivation in human cancer cell lines or tissues. This may account for the species-related functional
4 difference of the $CDKN2A$ gene. Th report supports this explanation that knocking out both $p16^{ink4a}$ and
5 $p19^{arf}$ leads to more cancer development than individual inactivation in mice (40). This also may account
6 that $P14^{ARF}$ exon-1 β deletion was not associated with GC metastasis whereas $CDKN2A$ CDR deletion was
7 significantly associated with GC metastasis as described above.

8 In conclusion, we have found estimated CDRs in many tumor suppressor genes in the cancer genome.
9 And there is a 5.1-kb CDR region within the $CDKN2A$ gene, and most $CDKN2A$ deletions lead to $P16^{INK4a}$ and
10 $P14^{ARF}$ inactivation in human cancers. Using the $CDKN2A$ CDR as a target sequence, we developed a
11 convenient quantitative multiplex PCR assay, the P16-Light, to detect $CDKN2A$ SCNVs in clinical practice,
12 suggesting that the strategy to detect $CDKN2A$ SCNVs may be suitable for the establishment of SCNV
13 detection methods for other tumor suppressor genes.

14 **Abbreviations**

15 CDR, common deletion region;

16 DHPLC, denaturing high performance liquid chromatography

17 GC, gastric carcinoma

18 LOH, loss of heterozygosity

19 MSI, microsatellite instability

20 OMIM, the Online Mendelian Inheritance in Man;

21 SCND, somatic copy number deletion

22 SM, surgical margin

23 TCGA, The Cancer Genome Atlas

24 WGS, whole genome sequencing

25 **Ethical approval and consent to participate:** The Institution Review Board of Peking University Cancer
26 Hospital & Institute approved this study and was carried out in accordance with the principles outlined in
27 the Declaration of Helsinki. Informed consent was obtained from each patient prior to their inclusion in the
28 study.

29 **Consent for publication:** Not applicable.

1 **Availability of supporting data:** Detailed information on the base-resolution interstitial common deletion
2 region in the *CDKN2A* gene in 110 cancer samples and other data were provided in Supplementary Data
3 files 1-14.

4 **Competing Interests:** DD, YT, JZ, and ZL are the creators for the pending patent "A quantitative method for
5 detection of human *CDKN2A* gene copy number using a primer set and their applications"
6 (PCT/CN2019/087172; WO2020228009). All of other authors have nothing to disclose.

7 **Funding:** This work was supported by the Beijing Natural Science Foundation (grant number 7181002 to DD);
8 Beijing Capital's Funds for Health Improvement and Research (grant number 2018-1-1021 to DD.). The
9 funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
10 manuscript.

11 **Author contributions:** DD designed the study, performed bioinformatics analyses, characterized base
12 resolution *CDR* coordinates in *CDKN2A* and other genes, and wrote the manuscript draft. JZ, YT, ZJL, and LKG
13 developed the P16-Light assay and analyzed *CDKN2A* SCNVs in samples. RX and YYL provided the *CDKN2A*
14 *CDR* coordinates from whole genome sequencing datasets. All authors approved the final manuscript.

15 **Acknowledgements:** We thank Dr. Sanford Dawsey at NCI, NIH, Bethesda, Maryland for critical comments
16 for the manuscript. We also thank Miss Gina Mckeown in New York, USA for English language editing.

17 **Authors' information:** Professor Dajun Deng graduated from Peking Union Medical College in 1986 and
18 employed by Peking University Cancer Hospital (Beijing Institute for Cancer Research) from then on. His
19 current research activities are focused on genetic and epigenetic *CDKN2A* inactivation in cancer
20 development. He published approximately 150 scientific papers, including *Mol Cancer*, *Nucl Acids Res*,
21 *Genome Biol*, *Proc Nat Acad Sci USA*, *Clin Cancer Res*, and *EBioMed*. His ORCID is 0000-0001-5161-5943.

22 **References**

- 23 1. Beroukhi R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, et al. The
24 landscape of somatic copy-number alteration across human cancers [eng]. *Nature* 2010 Feb;463
25 7283:899-905 as doi: 10.1038/nature08822.
- 26 2. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, et al. The cBio cancer
27 genomics portal: an open platform for exploring multidimensional cancer genomics data [eng].
28 *Cancer Discov* 2012 May;2 5:401-4 as doi: 10.1158/2159-8290.CD-12-0095.

- 1 3. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhi R, Getz G. GISTIC2.0 facilitates
2 sensitive and confident localization of the targets of focal somatic copy-number alteration in
3 human cancers [eng]. *Genome Biol* 2011;12 4:R41. Epub 2011/04/28 as doi:
4 10.1186/gb-2011-12-4-r41.
- 5 4. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, et al. Integrative analysis of
6 complex cancer genomics and clinical profiles using the cBioPortal [eng]. *Sci Signal* 2013 Apr;6
7 269:pl1. Epub 2013/04/02 as doi: 10.1126/scisignal.2004088.
- 8 5. Network CGAR, University AWGA, Agency BC, Hospital BaWs, Institute B, University B, University
9 CWR, et al. Integrated genomic characterization of oesophageal carcinoma [eng]. *Nature* 2017 01
10 12;541 7636:169-75. Epub 20170104 as doi: 10.1038/nature20805.
- 11 6. Cui Y, Chen H, Xi R, Cui H, Zhao Y, Xu E, Yan T, et al. Whole-genome sequencing of 508 patients
12 identifies key molecular features associated with poor prognosis in esophageal squamous cell
13 carcinoma [eng]. *Cell Res* 2020 10;30 10:902-13. Epub 20200512 as doi:
14 10.1038/s41422-020-0333-6.
- 15 7. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho R. Role of the INK4a locus in tumor
16 suppression and cell mortality. [eng]. *Cell* 1996 Apr;85 1:27-37.
- 17 8. Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, et al. CDK4/6 Inhibition Augments
18 Antitumor Immunity by Enhancing T-cell Activation [eng]. *Cancer Discov* 2018 02;8 2:216-33. Epub
19 2017/11/03 as doi: 10.1158/2159-8290.CD-17-0915.
- 20 9. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, et al. A Cancer Cell
21 Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade [eng]. *Cell* 2018 11;175
22 4:984-97.e24 as doi: 10.1016/j.cell.2018.09.006.
- 23 10. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, et al. Cyclin D-CDK4 kinase destabilizes
24 PD-L1 via cullin 3-SPOP to control cancer immune surveillance [eng]. *Nature* 2018 01;553
25 7686:91-5. Epub 2017/11/16 as doi: 10.1038/nature25015.
- 26 11. Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, Yin T, et al. Genetic Aberrations in the CDK4 Pathway Are
27 Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous
28 Melanoma [eng]. *Clin Cancer Res* 2019 Nov;25 21:6511-23. Epub 2019/08/02 as doi:
29 10.1158/1078-0432.CCR-19-0475.

- 1 12. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, et al. COSMIC: the
2 Catalogue Of Somatic Mutations In Cancer [eng]. Nucl Acids Res 2019 Jan; 47 D1:D941–7. Epub
3 2019/01/08 as doi: 10.1093/nar/gky1015.
- 4 13. Xing R, Zhou Y, Yu J, Yu Y, Nie Y, Luo W, Yang C, et al. Whole-genome sequencing reveals novel
5 tandem-duplication hotspots and a prognostic mutational signature in gastric cancer [eng]. Nat
6 Commun 2019 05;10 1:2037. Epub 2019/05/02 as doi: 10.1038/s41467-019-09644-6.
- 7 14. Sobin L, Gospodarowicz M, Wittekind C. (2009) TNM Classification of Malignant Tumours, 7th edn.
8 International Union Against Cancer (UICC). Wiley Press, New York, USA.
- 9 15. Berggren P, Kumar R, Sakano S, Hemminki K, Wada T, Steineck G, Adolfsson J, et al. Detecting
10 homozygous deletions in the CDKN2A(p16INK4a)/ARF(p14ARF) gene in urinary bladder cancer
11 using real-time quantitative PCR [eng]. Clin Cancer Res 2003 01;9: 235-42.
- 12 16. Carter SL, Cibulskis K, Helman E, Mckenna A, Shen H, Zack T, Laird PW. et al. Absolute
13 quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012 05;30 5:413–21.
14 as doi: 10.1038/nbt.2203
- 15 17. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, et al. Frequency of homozygous
16 deletion at p16/CDKN2 in primary human tumours [eng]. Nat Genet 1995 Oct;11 2:210-2 as doi:
17 10.1038/ng1095-210.
- 18 18. Novara F, Beri S, Bernardo ME, Bellazzi R, Malovini A, Ciccone R, Cometa AM, et al. Different
19 molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood [eng].
20 Hum Genet 2009 Oct;126 4:511-20. Epub 20090530 as doi: 10.1007/s00439-009-0689-7.
- 21 19. Xie H, Rachakonda PS, Heidenreich B, Nagore E, Sucker A, Hemminki K, Schadendorf D, et al.
22 Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL
23 fusion transcripts [eng]. Oncotarget 2016 Mar 29;7 13:16490-504 as doi:
24 10.18632/oncotarget.7503.
- 25 20. Patel A, Schwab R, Liu YT, Bafna V. Amplification and thrifty single-molecule sequencing of
26 recurrent somatic structural variations [eng]. Genome Res 2014 Feb;24 2:318-28. Epub 20131204
27 as doi: 10.1101/gr.161497.113.
- 28 21. Norris AL, Kamiyama H, Makohon-Moore A, Pallavajjala A, Morsberger LA, Lee K, Batista D, et al.
29 Transflip mutations produce deletions in pancreatic cancer [eng]. Genes Chromosomes Cancer
30 2015 Aug;54 8:472-81. Epub 20150529 as doi: 10.1002/gcc.22258.

- 1 22. Guney S, Bertrand P, Jardin F, Ruminy P, Kerckaert JP, Tilly H, Bastard C. Molecular characterization
2 of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B
3 exon 2 in diffuse large B-cell lymphomas [eng]. *Genes Chromosomes Cancer* 2011 Sep;50 9:715-25.
4 Epub 20110602 as doi: 10.1002/gcc.20893.
- 5 23. Florl AR, Schulz WA. Peculiar structure and location of 9p21 homozygous deletion breakpoints in
6 human cancer cells [eng]. *Genes Chromosomes Cancer* 2003 Jun;37 2:141-8 as doi:
7 10.1002/gcc.10192.
- 8 24. Kitagawa Y, Inoue K, Sasaki S, Hayashi Y, Matsuo Y, Lieber MR, Mizoguchi H, et al. Prevalent
9 involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid
10 leukemia [eng]. *J Biol Chem* 2002 Nov 29;277 48:46289-97. Epub 20020912 as doi:
11 10.1074/jbc.M208353200.
- 12 25. Sasaki S, Kitagawa Y, Sekido Y, Minna JD, Kuwano H, Yokota J, Kohno T. Molecular processes of
13 chromosome 9p21 deletions in human cancers [eng]. *Oncogene* 2003 Jun;22 24:3792-8 as doi:
14 10.1038/sj.onc.1206589.
- 15 26. Cayuela JM, Gardie B, Sigaux F. Disruption of the multiple tumor suppressor gene
16 MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic
17 leukemias [eng]. *Blood* 1997 Nov 01;90 9:3720-6.
- 18 27. Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D, Bièche I. Characterization of a germ-line
19 deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family:
20 identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF [eng].
21 *Cancer Res* 2007 Apr 15;67 8:3963-9 as doi: 10.1158/0008-5472.CAN-06-2004.
- 22 28. Raschke S, Balz V, Efferth T, Schulz WA, Florl AR. Homozygous deletions of CDKN2A caused by
23 alternative mechanisms in various human cancer cell lines [eng]. *Genes Chromosomes Cancer* 2005
24 Jan;42 1:58-67 as doi: 10.1002/gcc.20119.
- 25 29. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, et al.
26 Germline p16 mutations in familial melanoma [eng]. *Nat Genet* 1994 Sep;8 1:15-21 as doi:
27 10.1038/ng0994-15.
- 28 30. Freedberg DE, Rigas SH, Russak J, Gai W, Kaplow M, Osman I, Turner F, et al. Frequent
29 p16-independent inactivation of p14ARF in human melanoma [eng]. *J Natl Cancer Inst* 2008
30 Jun;100 11:784-95. Epub 2008/05/27 as doi: 10.1093/jnci/djn157.

- 1 31. Harinck F, Kluijft I, van der Stoep N, Oldenburg RA, Wagner A, Aalfs CM, Sijmons RH, et al. Indication
2 for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas [eng]. J
3 Med Genet 2012 Jun;49 6:362-5. Epub 2012/05/25 as doi: 10.1136/jmedgenet-2011-100563.
- 4 32. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man
5 (OMIM), a knowledgebase of human genes and genetic disorders [eng]. Nucleic Acids Res 2005
6 Jan;33 Database issue:D514-7 as doi: 10.1093/nar/gki033.
- 7 33. Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick's Online Mendelian Inheritance in Man
8 (OMIM) [eng]. Nucleic Acids Res 2009 Jan;37 Database issue:D793-6. Epub 2008/10/08 as doi:
9 10.1093/nar/gkn665.
- 10 34. Qiao JL, Tian Y, Cheng XJ, Liu ZJ, Zhou J, Gu LK, Zhang BZ, et al. CDKN2A deletion leading to
11 hematogenous metastasis of human gastric carcinoma. Frontiers in Oncology 2021 Dec 06; DOI:
12 10.3389/fonc.2021.801219.
- 13 35. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, et al. Comparative
14 Molecular Analysis of Gastrointestinal Adenocarcinomas [eng]. Cancer Cell 2018 04 09;33
15 4:721-35.e8. Epub 20180402 as doi: 10.1016/j.ccell.2018.03.010.
- 16 36. Peters G. Tumor suppression for ARFionados: the relative contributions of p16INK4a and p14ARF
17 in melanoma [eng]. J Natl Cancer Inst 2008 Jun 04;100 11:757-9. Epub 20080527 as doi:
18 10.1093/jnci/djn156.
- 19 37. Cui CH, Gan Y, Gu LK, Wilson J, Liu ZJ, Zhang BZ, Deng DJ. P16-specific DNA methylation by
20 engineered zinc finger methyltransferase inactivates gene transcription and promotes cancer
21 metastasis [eng]. Genome Biol 2015 Nov 23;16:252. doi: 10.1186/s13059-015-0819-6.
- 22 38. Li Q, Wang XH, Lu ZM, Zhang BZ, Guan ZP, Liu ZJ, Zhong QM, et al. Polycomb CBX7 directly controls
23 trimethylation of histone H3 at lysine 9 at the p16 locus [eng]. PLoS One 2010 Oct 29;5(10):e13732.
24 doi: 10.1371/journal.pone.0013732.
- 25 39. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, Blasco MA, et al. The Ink4/Arf locus is
26 a barrier for iPS cell reprogramming [eng]. Nature 2009 Aug 27;460 7259:1136-9. Epub 20090809
27 as doi: 10.1038/nature08290.
- 28 40. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact
29 of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis [eng]. Oncogene 2004
30 Jan;23 2:379-85 as doi: 10.1038/sj.onc.1207074.

1 **Figure Legends**

2 **Figure 1.** Genomic coordinates of interstitial *CDKN2A* deletion/fusion in human cancer genomes. (A)
3 Estimated coordinates of *CDKN2A* deep-deletion in cancer tissues according to the COSMIC data. (B) True
4 coordinates at the base-resolution of *CDKN2A* deletion in cancer cell lines ($n=92$, blue lines) and gastric
5 cancer ($n=18$, purple lines) according to sequencing data. Two top charts display the coordinates of most
6 deletion fragments. The sample ID is labeled under each column. Two bottom charts display the amplified
7 view of these deletion fragments, where the 17-kb and 5.1-kb common deletion regions (CDRs) are
8 highlighted with a red dashed line rectangle. The 5.1-kb true CDR from the *P16^{INK2a}* promoter to intron-2 is
9 exactly the same region as the deleted *CDKN2A* fragment in the HCC193 lung cancer cell line (highlighted
10 with a black line). Each line represents a *CDKN2A* deletion fragment. The locations of *P16^{INK4a}* and *P14^{ARF}*
11 (grey shadow) and exon-1 α /1 β /2/3 (black dots) are also labeled as landmarks. The position of amplicons for
12 P16-Light and P14-qPCR are respectively illustrated with violet and green lines. The detailed deletion
13 coordinates for each sample are listed in Data file 2 and Data file 12.

14 **Figure 2.** The estimated coordinates of deep-deletion fragments overlapped with tumor suppressor genes *ATM*,
15 *FAT1*, *RB1*, *PTEN*, and *miR31HG* according to the COSMIC data. Common deletion region (CDR) for each gene is
16 highlighted with a red line rectangle. The detailed deletion coordinates for each sample are listed in Data
17 file 3 and Data file 11.

18 **Figure 3.** Detection of the copy number of *CDKN2A* intron-2 with quantitative gene-specific multiplex PCR
19 (P16-Light). (A) The location of the 129-bp amplicon within the common deletion region (CDR) and its host
20 genes. (B) The amplification efficiency of two amplicons for *GAPDH* and *CDKN2A* genes in the template
21 titration assays using standard DNA samples from RKO cells (with two wild-type *CDKN2A* alleles) and A549
22 cells (with a homozygous *CDKN2A* deletion). (C) Effects of the amount of template DNA on the efficiency of
23 PCR amplification for amplicons in *CDKN2A* and *GAPDH* genes (Left chart) and detection of the relative
24 *CDKN2A* gene copy number (Right chart). (D) The linear relationship between the proportion of *CDKN2A*
25 copy number deletion and ratios of RKO cells spiked with A549 cells. (E) Stability of the proportion of the
26 *CDKN2A* copy number deletion by P16-Light during ten experiments over different days. The RKO cell DNA
27 templates were spiked with 0, 10%, 20%, 25%, and 30% A549 cell DNA. Each column represents the average
28 proportion of *CDKN2A* copy number deletion in triplicate. Exp. 1 - 10: the results of 10 repeated

1 experiments performed on different days. *: compared to the 100% RKO control in chi-square test, $p < 0.05$.

2 **Figure 4.** Comparisons of somatic copy number variations (SCNVs) of *CDKN2A* gene in gastric carcinoma
3 samples (GCs) from 156 patients in the P16-Light and WGS (30×) analyses. (A) The states of *CDKN2A* SCNVs
4 by P16-Light (relative to paired surgical margin reference) in GC groups with and without *CDKN2A*
5 deletion/fusion in the WGS analysis. (B) Comparison of the proportion of cancer cells (or sample purity; by
6 WGS) in GC groups with various *CDKN2A* SCNVs by P16-Light. The average proportion of cancer cells in each
7 GC group is labeled. (C) Correlation analysis between the proportion and relative copy number of the
8 *CDKN2A* gene in GCs.

9

1

Table 1. Oligo sequences

Gene/STS	Assay	Oligo	Sequence (5'-3')	PCR product size
<i>CDKN2A</i>	P16-Light	F-primer	caggtctgttctcatttg	129-bp
	P16-Light	R-primer	ggtcagattagttgagtttg	
	P16-Light	Probe	FAM-ctggctggaccaacctcagg-BHQ1	
	P14-qPCR	F-primer	ggaggcggcgagaacat	92-bp
	P14-qPCR	R-primer	tgaaccacgaaaacctcact	
	P14-qPCR	Probe	VIC-tgcgcaggttcttggtgacctcc-TAMRA	
<i>GAPDH</i>	P16-Light	F-primer	gtcacatattctggaggag	135-bp
	P16-Light	R-primer	ggtcattgatggcaacaata	
	P16-Light	Probe	Cy5-tgccttctgcctctgtctctt-BHQ2	
	P14-qPCR	F-primer	ccactaggcgtcactgttct	97-bp
	P14-qPCR	R-primer	gcgaactcaccgttgact	
	P14-qPCR	Probe	FAM-ctccctccgcgacccgagc-TAMRA	

2



3

1 **Table 2.** Association between clinicopathological characteristics and *CDKN2A* SCND
 2 detected by P16-Light and P14-qPCR

		<i>CDKN2A</i> CDR SCND-positive by P16-Light		<i>CDKN2A P14^{ARF}</i> SCND-positive by P14-qPCR		<i>CDKN2A</i> CDR or <i>P14^{ARF}</i> SCND-positive		<i>CDKN2A</i> CDR & <i>P14^{ARF}</i> SCND-positive		
		<i>n</i>	cases	Positive rate (%)	Positive cases	Positive rate (%)	Positive cases	Positive rate (%)	Positive cases	Positive rate (%)
Age	<60	68	23	33.8	18	26.5	33	48.5	8	11.8
	≥60	71	28	39.4	26	36.6	43	60.6	11	15.5
Sex	Male	101	40	39.6	33	32.7	58	57.4	15	14.9
	Female	38	11	28.9	11	28.9	18	47.4	4	10.5
Location ^a	Cardiac	18	9	50.0	3	16.7	10	55.6	2	11.1
	Non-cardiac	121	42	34.7	41	33.9	66	54.5	17	14.0
Different.	Poor	99	33	33.3	30	30.3	51	51.5	12	12.1
	Well/mod.	37	16	43.2	14	37.8	23	62.2	7	18.9
pTNM	I-II	46	11	23.9^a	16	34.8	23	50.0	4	8.7
stage	III	37	14	37.8	8	21.6	17	45.9	5	13.5
	IV	56	26	46.4	20	35.7	36	64.3	10	17.9
Invasion	T1-2	27	11	40.7	13	48.1	19	70.4	5	18.5
	T3	79	28	35.4	19	24.1	38	48.1	9	11.4
	T4	33	12	36.4	12	36.4	19	57.6	5	15.2
Lymph	Negative	51	16	31.4	18	35.3	27	52.9	7	13.7
metastasis	Positive	88	35	39.8	26	29.5	49	55.7	12	13.6
Distant	Negative	107	31	29.0^b	33	30.8	53	49.5^c	11	10.3 ^d
	Positive	32	20	62.5	11	34.4	23	71.9	8	25.0
(Total)		139	51	36.7	44	31.7	76	54.7	19	13.7

3 ^a Chi-square trend test, $p < 0.001$; ^b Odds ratio (OR) = 4.09, 95% confidence interval (CI) (4.66-10.19), $p = 0.001$;

4 ^c OR = 2.60, 95%CI (1.03-6.74), $p < 0.026$; ^d OR = 2.91, 95%CI (0.94-8.94), $p = 0.033$



Estimated genomic coordinates of deep-deleted fragments of gene in TCGA cancers by SNP-array (kb, hg19)

